Floatz logo

Tislelizumab

Primary Mediastinal Large B-Cell Lymphoma

Ruijin Hospitalmonoclonal_antibodyPhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
81/ 100

Competitive context

87 Active assets in the Primary Mediastinal Large B-Cell Lymphoma cohort.

Asset / SponsorPhaseRating
Ifosfamide
David Bond, MD
Phase 4BBB
ETOPOSIDE
University of Washington
Phase 4BBB
Inno-206
University of Washington
Phase 4BBB
Cyclophosphamide
University of Washington
Phase 4BBB
(+)-VINCRISTINE
Sun Yat-sen University
Phase 4BBB

View all 50 →

Same molecule, other indications

Tislelizumab is also rated in:

non-small cell lung carcinomaDormant
BB
Indicative ·
69 / 100
View asset →
Hepatic Metastasis of Pancreatic CancerDormant
BB
Indicative ·
69 / 100
View asset →
Primary Peritoneal Cavity CancerDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →